Off-label Avastin in AMD: the European Commission gets involved
This article was originally published in SRA
Executive Summary
The controversy over the off-label use of Roche's Avastin (bevacizumab) in wet AMD has spread beyond national borders and is now on the EU agenda, after the European Commission said it was planning to launch a study of off-label prescribing to better understand the various aspects of off-label prescribing, which is not currently regulated at EU level.